Effectiveness of biosimilar infliximab in the treatment of ocular inflammatory disease

被引：0
|
作者：
Lien, Eric [1 ]
Ambrosino, Christina [2 ]
Mallem, Krishna [1 ,3 ]
Shen, Leo [2 ]
Huang, Peng [4 ,5 ]
Berkenstock, Meghan [3 ]
机构：
[1] Drexel Univ, Coll Med, Philadelphia, PA USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Med, Wilmer Eye Inst, Baltimore, MD USA
[4] Johns Hopkins Univ, Biostat & Bioinformat Div, Dept Oncol, Sch Med, Baltimore, MD USA
[5] Johns Hopkins Univ, Dept Biostat, Ctr Teaching & Learning, Baltimore, MD USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Infliximab therapy for the treatment of refractory ocular inflammatory disease
    Sobrin, Lucia
    Kim, Eva C.
    Christen, William
    Papadaki, Thekla
    Letko, Erik
    Foster, C. Stephen
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (07) : 895 - 900
  • [2] Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
    Lichtenstein, Gary R.
    Soonasra, Arif
    Latymer, Mark
    Singh, Sheena
    Feagan, Brian G.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (07) : 691 - 708
  • [3] Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients
    Eberl, Anja
    Huoponen, Saara
    Pahikkala, Tapio
    Blom, Marja
    Arkkila, Perttu
    Sipponen, Taina
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (12) : 1348 - 1353
  • [4] CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease
    Albshesh, Ahmad
    Ben-Horin, Shomron
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 971 - 978
  • [5] A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
    Farkas, Klaudia
    Molnar, Tamas
    [J]. IMMUNOTHERAPY, 2018, 10 (02) : 107 - 117
  • [6] Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients
    Guardiola, J.
    Rodriguez Alonso, L.
    Padulles, N.
    Santacana, E.
    Serra, K.
    Padulles, A.
    Ruiz-Cerulla, A.
    Gilabert, P.
    Arajol, C.
    Ibanez-Sanz, G.
    Camps, B.
    Colom, H.
    Bas, J.
    Morandeira, F.
    Sanchez, E.
    Orobitg, J.
    Rodriguez Moranta, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S441 - S441
  • [7] Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease
    O'Connell, Daniel M.
    Nachreiner, Joshua
    Shu, Xin
    Terry, Erica
    Imburgia, Taylor
    Vanderloo, Joshua
    Lasarev, Michael R.
    Bogenschutz, Monica
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2022, 74 (05): : 605 - 609
  • [8] Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases
    Kam, Ka Wai
    Tam, Lai Shan
    Tam, Mang Kwan Patrick
    Ophth, F. C.
    Young, Alvin L.
    [J]. ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2015, 4 (01): : 19 - 24
  • [9] Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease
    Muhammed, R.
    Whyte, L.
    Protheroe, S.
    Bremner, R.
    Haller, W.
    Wong, T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S291 - S291
  • [10] COMPARISON OF EFFICACY AND SAFETY OF BIOSIMILAR INFLIXIMAB TO ORIGINATOR INFLIXIMAB IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
    Muhammed, R.
    Wong, T.
    Haller, W.
    Protheroe, S.
    Whyte, L.
    Bremner, R.
    [J]. GUT, 2016, 65 : A259 - A260
12345